Satraplatin Enters Phase II Study for Metastatic Breast Cancer

A new phase II study has been opened for accrual, evaluating satraplatin, a drug candidate from GPC Biotech, AG, (GPCB), in patients with metastatic breast cancer who have received no more than one prior chemotherapy treatment regimen. The study is being managed by US Oncology, a healthcare-services network dedicated to cancer treatment and research. This trial aims to assess the effectiveness of satraplatin in this patient population, with 57 research sites in the US Oncology network participating. The primary objective is to determine the objective response rate of satraplatin.

Key Takeaways:

• Satraplatin, a lead drug candidate from GPC Biotech, AG, (GPCB), is undergoing a phase II study in patients with metastatic breast cancer.
• The study is being managed by US Oncology, a healthcare-services network dedicated exclusively to cancer treatment and research, with 57 research sites participating.
• The primary objective of the study is to determine the objective response rate of satraplatin in patients with metastatic breast cancer.
• Satraplatin is also in a phase III registrational trial as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer.
• GPCB is opening new clinical studies to explore the potential of satraplatin in additional tumor types.
• Joyce O'Shaughnessy, MD, codirector of US Oncology's breast cancer research committee, expresses enthusiasm for the potential of satraplatin in treating breast cancer.

Statistics:

• 57 research sites in the US Oncology network plan to participate in the trial.
• The study is expected to enroll 80 patients.
• The primary objective is to determine the objective response rate of satraplatin in patients with metastatic breast cancer.
• Satraplatin is currently in a phase III registrational trial for hormone-refractory prostate cancer.

Sources:

• Health & Medicine Week editors.
• GPC Biotech, AG, (GPCB).
• US Oncology.
• NewsRx.com.